PBE - ETF AI Analysis
Top Page
Invesco Dynamic Biotechnology & Genome ETF (PBE)
Rating:72Outperform
Price Target:―
Positive Factors
Leading Biotech Holdings
Several top positions, including United Therapeutics, Protagonist Therapeutics, and TG Therapeutics, have shown strong gains, helping support the fund’s overall results.
Focused Exposure to Health Care Innovation
The ETF is heavily invested in U.S. biotechnology and genome companies, giving investors targeted exposure to a key growth area in health care.
Recent Short-Term Momentum
The fund’s performance over the past month has been strong, indicating improving short-term momentum despite weaker results over longer periods.
Negative Factors
High Sector Concentration
Almost all assets are in the health care sector, so the fund is highly sensitive to swings in biotech and pharmaceutical markets.
Limited Geographic Diversification
With nearly all holdings in U.S. companies, investors get little protection from downturns in the U.S. market.
Relatively High Expense Ratio
The fund’s fee is on the higher side for an ETF, which can eat into returns over time, especially if performance remains uneven.
PBE vs. SPDR S&P 500 ETF (SPY)
AUM252.64M
RegionNorth America
Expense Ratio0.58%
Beta0.74
IssuerInvesco
Inception DateJun 23, 2005
Dividend Yield1.06%
Asset ClassEquity
Index TrackedDynamic Biotech & Genome Intellidex Index (AMEX)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,098
30 Day Avg. Volume6,903
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
104.97Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PBE Summary
The Invesco Dynamic Biotechnology & Genome ETF (PBE) tracks the Dynamic Biotech & Genome Intellidex Index, focusing on U.S. biotech and genome companies working on new drugs and genetic treatments. It holds well-known names like Amgen and Gilead Sciences, along with smaller, fast-moving innovators. Someone might invest in PBE to seek long-term growth from medical breakthroughs and to get a basket of biotech stocks in a single investment instead of picking individual companies. However, biotech shares can be very volatile, so the ETF’s price can swing sharply and may go up or down more than the overall market.
How much will it cost me?The expense ratio for the Invesco Dynamic Biotechnology & Genome ETF (PBE) is 0.58%, which means you’ll pay $5.80 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on specialized biotechnology and genomic research companies that require more in-depth analysis and management.
What would affect this ETF?The Invesco Dynamic Biotechnology & Genome ETF (PBE) could benefit from advancements in biotechnology and genomic research, as well as increased demand for innovative healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, or economic downturns that could impact funding for biotech companies. The ETF’s focus on U.S.-based firms and top holdings like Vertex Pharmaceuticals and Gilead Sciences highlights its reliance on the performance of leading biotech innovators.
PBE Top 10 Holdings
PBE is a pure-play U.S. biotech fund, and its story right now is all about a tug-of-war between surging innovators and wobblier heavyweights. United Therapeutics, Biogen, and a fast-climbing Protagonist Therapeutics are doing the heavy lifting, with TG Therapeutics adding extra fuel as one of the fund’s hottest names. On the other side, Alnylam is losing steam and acting as a noticeable drag, while Illumina and Incyte are more mixed. With nearly all its chips on health care and biotech, this ETF is highly concentrated in one high-risk, high-reward corner of the market.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| United Therapeutics | 6.12% | $15.73M | $23.94B | 83.30% | 79 Outperform | |
| Illumina | 5.91% | $15.18M | $21.47B | 79.82% | 71 Outperform | |
| Biogen | 5.09% | $13.08M | $27.73B | 50.02% | 74 Outperform | |
| Incyte | 4.89% | $12.56M | $19.39B | 51.00% | 81 Outperform | |
| Regeneron | 4.67% | $11.99M | $68.12B | 7.66% | 78 Outperform | |
| Gilead Sciences | 4.56% | $11.70M | $162.26B | 22.26% | 78 Outperform | |
| Amgen | 4.38% | $11.24M | $178.95B | 24.10% | 77 Outperform | |
| Alnylam Pharma | 4.37% | $11.23M | $39.85B | 3.98% | 60 Neutral | |
| TG Therapeutics | 3.79% | $9.74M | $6.09B | 14.60% | 65 Neutral | |
| Catalyst Pharma | 3.50% | $8.99M | $3.82B | 29.74% | 83 Outperform |
PBE Technical Analysis
Positive
―
Price Trends
79.67
Positive
80.80
Positive
77.07
Positive
Market Momentum
0.45
Positive
55.81
Neutral
36.28
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PBE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 81.14, equal to the 50-day MA of 79.67, and equal to the 200-day MA of 77.07, indicating a bullish trend. The MACD of 0.45 indicates Positive momentum. The RSI at 55.81 is Neutral, neither overbought nor oversold. The STOCH value of 36.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBE.
PBE Peer Comparison
Comparison Results
Performance Comparison
PBE
Invesco Dynamic Biotechnology & Genome ETF
82.05
21.03
34.46%
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
SBIO
ALPS Medical Breakthroughs ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents